A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles Using Pathway-Drug Network

<div>The candidate drug MS-275 on the validation network. MS-275 has a strong target relationship with the breast cancer genes HDAC1, TP53, CASP3, CCND1, and CYP3A4. Furthermore, it has an indirect relationship with the well-known breast cancer gene BRCA1.</div>

BioMed Research International

fig8

Figure 8

Figure 8: A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles Using Pathway-Drug Network 